Johnson & Johnson acquires Yellow Jersey Therapeutics and with it NM 26 for skin inflammation and skin itch.
Johnson & Johnson1 announced that it has successfully completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics to secure the global rights to NM 26, a novel, investigational first-in-class bispecific antibody, in an all-cash transaction of approximately $1.25 billion, as announced on May 28, 2024. NM26, which is ready to enter Phase II studies in atopic dermatitis (AD), targets two clinically proven pathways, IL-4R alpha subunit (IL-4R?) and IL-31, which trigger Th2-mediated skin inflammation and skin itch, respectively.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins